Company Overview of Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals Limited operates as a pharmaceutical company worldwide. The company develops branded and generic formulations for humans and animals; active pharmaceutical ingredients; biotechnology products and diagnostic kits; and plant tissue cultures. It also offers contract research and contract manufacturing services. The company offers its products for various therapeutic areas, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives, antibiotics, respiratory, anti diabetics, immunologicals, antipyretics, anthelmintics, anti-hypertensives, anti-inflammatory preparations, antibacterials, vitamins, iron and protein tonics, and ophthalmology. It has a ...
Key Executives for Cadila Pharmaceuticals Limited
Chairman and Managing Director
Compensation as of Fiscal Year 2014.
Cadila Pharmaceuticals Limited Key Developments
NovaSAID AB Announces Strategic Partnership with Cadila Pharmaceuticals Limited to Develop Innovative Treatments in Inflammation and Pain Management
Jan 10 14
NovaSAID AB and Cadila Pharmaceuticals Ltd. announced a strategic partnership to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis. The companies will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID and the development will be onducted at Cadila Pharmaceuticals’ facility in Ahmedabad, India. According to the agreement, all revenue generated from the sale and marketing in India, Middle East and Africa of products covered by the agreement will be retained by Cadila and net sales in all other countries will be shared by the two companies. Cadila will bear all costs associated with the program through to Phase II. Many of the medical treatments for inflammation and pain are associated with unwanted side effects such as an increased risk for myocardial infarction and gastric ulcers. NovaSAID’s drug candidates targets an enzyme called microsomal prostaglandin E synthase -1 (mPGES-1), a critically important mediator of inflammation and pain, which theoretically should reduce the risk for side effects. The collaboration with Cadila will provide the resources to take this program into clinical development and further towards the market.
Cadila Pharma to Launch Low-Cost Lung Cancer Drug in India
Nov 22 13
Cadila Pharmaceuticals plans to launch an innovative drug for the treatment of non-small-cell lung cancer (NSCLC) in the Indian market by December 2014. The drug, which will be marketed under the brand name Mycidac-C, targets desmocolin-3 protein. The drug will reportedly be sold at a 'low cost' - a course of 10 injections being priced at INR 40,000.
Helperby and Cadila Pharmaceuticals Announces Research Partnership and Licensing Agreement for Development of Products to Tackle Antibiotic Resistance
Nov 18 13
Helperby and Cadila Pharmaceuticals have announced a research partnership and licensing agreement aimed at the development of products to tackle antibiotic resistance. The deal involves Cadila licensing Helperby's HT61, a candidate antibiotic resistance breaker, from clinical trial stages to regulatory approval and commercialisation. Cadila will also be responsible for combining HT61 with existing antibiotics. A copy of the Helperby press release can be accessed here. The partnership is likely to leverage Cadila's experience in clinical development and regulatory approval. ARBs offer a potential weapon against antibiotic resistance and are being combined with existing obsolete antibiotics in order to make them once again effective in fighting bacterial infections. With the threat of antibiotic resistance growing, companies are likely to look increasingly towards technology such as ARBs for a means of neutralising it.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|